Abstract | BACKGROUND: Clinical studies suggest a role for angiogenesis in the development and persistence of chronic asthma, but whether angiogenic mediators contribute to acute asthma has not been fully studied. OBJECTIVE: METHODS: We sensitized BALB/c mice with ovalbumin. We measured serum VEGF and examined immunoreactive VEGF around the airways 48 hours after the last challenge with either aerosolized PBS or ovalbumin once per day for 3 days. We also treated ovalbumin-sensitized mice with either endostatin/Fc or control fusion protein at the time of challenge with ovalbumin. We analyzed allergic airway responses 48 hours after the last ovalbumin challenge. RESULTS: CONCLUSION: These data demonstrate for the first time that recombinant endostatin can prevent the development of asthma features in a mouse model and suggest that this class of agents merits further study as novel therapeutics for asthma.
|
Authors | Yasue Suzaki, Kaoru Hamada, Masayuki Sho, Toshihiro Ito, Kenichi Miyamoto, Satoru Akashi, Hisanori Kashizuka, Naoya Ikeda, Yoshiyuki Nakajima, Michiko Iwase, Ikuo Homma, Lester Kobzik, Hiroshi Kimura |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 116
Issue 6
Pg. 1220-7
(Dec 2005)
ISSN: 0091-6749 [Print] United States |
PMID | 16337449
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Endostatins
- Inflammation Mediators
- Recombinant Proteins
- Vascular Endothelial Growth Factor A
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Asthma
(immunology, physiopathology, prevention & control)
- Endostatins
(therapeutic use)
- Female
- Inflammation Mediators
(antagonists & inhibitors)
- Mice
- Mice, Inbred BALB C
- Recombinant Proteins
(therapeutic use)
- Vascular Endothelial Growth Factor A
(blood, physiology)
|